Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

With every new year bringing new technologies, expanding attack surfaces, and legions of salivating threat actors.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.